The Incidence of Pulmonary, Cardiovascular and Renal System Non-communicable Complications Associated with the Post-acute Phase of the Infection by Covid-19

Launched by HELLENIC INSTITUTE FOR THE STUDY OF SEPSIS · Sep 20, 2024

Keywords

ClinConnect Summary

This clinical trial, titled "The Incidence of Pulmonary, Cardiovascular and Renal System Non-communicable Complications Associated with the Post-acute Phase of the Infection by Covid-19," is investigating how COVID-19 can impact the lungs, heart, and kidneys even after recovery. Researchers have found that many people who have had COVID-19 may experience lasting health issues, with up to 70% showing some decline in how well their organs function even months after their diagnosis. The goal of this study is to learn more about these post-acute complications, identify ways to predict who might be at risk for developing long-term issues, and create guidelines to help healthcare providers improve care for these patients.

To participate in the trial, you must be an adult over 18 years old. There are different groups of participants: one group includes individuals who have never had COVID-19, while the other groups include people who have recovered from COVID-19, with one group experiencing no organ dysfunction and the other showing signs of organ issues during or after their infection. Participants can expect to share their health history and undergo evaluations to help researchers understand the long-term effects of COVID-19 on various organ systems. This important study aims to enhance our understanding of COVID-19’s impact and improve future care for those affected.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Group A (comparators)
• • 1. Adults (18 years or more) of both genders
• • 2. Negative history of acute COVID-19
• • Group B (patients with ΝΟ dysfunction)
• • 1. Adults (18 years or more) of both genders
• • 2. History of acute COVID-19 hospitalized or non-hospitalized. All cases appearing from start of the pandemic until the last six months may apply
• • 3. Absence of any current overt organ dysfunction
• • 4. Absence of signs of any organ dysfunction during acute COVID-19
• • Group C (patients with dysfunctions)
• • 1. Adults (18 years or more) of both genders
• • 2. History of acute COVID-19 hospitalized or non-hospitalized. All cases appearing from start of the pandemic until the last six months may apply
• • 3. Presence of signs of organ dysfunction of the lung, the kidneys or the heart during acute COVID-19
• Exclusion Criteria:
• • Group A (comparators)
• • 1. Any other co-existing disorder generating clinical symptoms
• • 2. Failure to thrive according to the attending physicians
• • 3. Pregnancy or lactation
• • Group B (patients with ΝΟ dysfunction)
• • 1. Any other co-existing disorder generating clinical symptoms
• • 2. Failure to thrive according to the attending physicians
• • 3. Pregnancy or lactation
• • Group C (patients with dysfunctions)
• • 1. Any other co-existing disorder generating clinical symptoms
• 2. Medical history of any of:
• • stage III or IV chronic obstructive pulmonary disease according to the GOLD criteria
• • pulmonary fibrosis or pulmonary hypertension
• • stage IV solid tumour malignancy under chemotherapy or radiotherapy
• • systemic sclerosis
• • congestive heart failure
• • stage II, III or IV dyspnoea according to the New York Heart Association classification before the acute COVID-19
• • 3. Limited chance of survival for at least six months due to co-existing comorbidity(-ies) according to the judgement of the attending physicians
• • 4. Pregnancy or lactation